Anti-viral compounds

US8338605B2 · kind B2 · utility

Assignee

• Abbott Laboratories · US

Inventors

• Todd W. Rockway · Gurnee, US
• David A. Betebenner · Lawrenceville, US
• Allan C. Krueger · Gurnee, US
• Nobuhiko Iwasaki · Buffalo Grove, US
• Curt S. Cooper · Vernon Hills, US
• David D. Anderson · Kenosha, US
• Dale J. Kempf · Libertyville, US
• Darold L. Madigan · Elk Grove Village, US
• Christopher E. Motter · Oak Creek, US
• Jason P. Shanley · Chicago, US
• Michael D. Tufano · Chicago, US
• Rolf Wagner · Antioch, US
• Rong Zhang · Zhejiang, CN
• Akteruzzaman Molla · Gurnee, US
• Hongmei Mo · Foster City, US
• Tami J. Pilot-Matias · Libertyville, US
• Sherie V L. Masse · Kenosha, US
• Robert J. Carrick · Pleasant Prairie, US
• Wenping He · Libertyville, US
• Liangjun Lu · Kildeer, US

Key dates

• Filing date: Jun 17, 2010
• Grant date: Dec 25, 2012
• Expiry date: Jun 17, 2030

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.